Reversible Causes of Peripheral Neuropathy and Their Treatment

Metabolic Causes

• Optimizing glycemic control can effectively prevent diabetic peripheral neuropathy progression in type 1 diabetes and may modestly slow progression in type 2 diabetes, though it doesn't reverse neuronal loss, as recommended by the American Diabetes Association 2

Medication-Induced Neuropathy

• Chemotherapy with platinum compounds, taxanes, vinca alkaloids, and bortezomib can cause neuropathy, and dose reduction or discontinuation may allow for recovery, according to the European Society for Medical Oncology 3
• Metronidazole is associated with peripheral neuropathy in 21-39% of cases, and typically improves with discontinuation, as reported by the European Crohn’s and Colitis Organisation 5

Inflammatory/Immune-Mediated Causes

• Chronic Inflammatory Demyelinating Polyneuropathy may respond to corticosteroids, immunosuppressants, or intravenous immunoglobulin, as suggested by the American Academy of Neurology 6

Nutritional/Toxic Causes

• Vitamin B6 toxicity can cause neuropathy, and discontinuation typically leads to improvement, as noted by the Mayo Clinic 7

Diagnostic Approach

• A comprehensive evaluation should include assessing for diabetes with fasting blood glucose and HbA1c, checking vitamin B12, methylmalonic acid, and homocysteine levels, and evaluating thyroid function with TSH, as recommended by the American Association of Clinical Endocrinologists 2
• Reviewing medication history for potential neurotoxic agents is crucial, as emphasized by the European Society for Medical Oncology 5

Treatment Approach

• First-line medications for painful neuropathy include gabapentin, pregabalin, duloxetine, and tricyclic antidepressants, as recommended by the American Academy of Neurology 7
• Non-pharmacological interventions such as regular physical activity, acupuncture, and cognitive behavioral therapy may also be beneficial, as suggested by the American Pain Society 1

Monitoring and Follow-up

• Annual assessment starting at diagnosis for type 2 diabetes and 5 years after diagnosis for type 1 diabetes is recommended for diabetic neuropathy, as advised by the American Diabetes Association 2
• Regular clinical monitoring during treatment with potentially neurotoxic medications is essential, as emphasized by the European Society for Medical Oncology 3